Real-world cross-comparison of metabolic outcomes with different sodium-glucose co-transporter 2 inhibitors agents in adults with type 2 diabetes: results from the Association of British Clinical Diabetologists audit programme

Authors

  • Tom Crabtree University Hospitals of Derby and Burton NHS Trust

DOI:

https://doi.org/10.15277/bjd.2024.449

Keywords:

SGLT2, real-world, HbA1c, weight, blood pressure

Abstract

Sodium-glucose co-transporter-2 inhibitors (SGLT2i) have demonstrated significant efficacy in improving cardiorenal and metabolic outcomes, However, whether there are differences between agents remain unclear. We therefore assessed changes in haemoglobin A1c (HbA1c), weight, body mass index (BMI) and systolic blood pressure (SBP) across the class; and between agents.

Methods: Individuals using empagliflozin (E), canagliflozin (C) or dapagliflozin (D) in the ABCD audits were included provided that data were available for the outcomes of interest. Multivariate linear regression analysis was used to assess adjusted change in HbA1c, weight, BMI and SBP and to compare outcomes between drugs. Analyses were performed in Stata 17.

Results: 21,263 individuals (E=11,231; C=2,257; D=7,775) with mean±SD age 60.0±10.4years, HbA1c 75.3±17.2 mmol/mol, BMI 33.9±7.1kg/m2 and 61.2% female were included. Over median follow-up of 1.7 years, HbA1c reduced by 10.0 mmol/mol (95% CI 9.8-10.2; p<0.001); weight reduced by 3.2 kg (95% CI 2.2-4.1; p<0.001); BMI reduced by 1.1 kg/m2 (95% CI 0.8-1.5; p<0.001) and SBP reduced by 0.9 mmHg (95% CI 0.7-1.1; p<0.001). Empagliflozin was associated with larger HbA1c reduction than dapagliflozin and canagliflozin (-10.6 mmol/mol [E] vs -9.8 mmol/mol [C] vs -9.1 mmol/mol [D]; p<0.001 for both). Canagliflozin was associated with statistically larger SBP reductions compared to dapagliflozin (-1.6 mmHg [C] vs 0.6 mmHg [D]). No differences were noted in weight and BMI change between drugs. Discontinuation of SGLT2i therapy was rare, only occurring in 0.35% (75/21,338). Our cohort has individuals with higher baseline weight and HbA1c compared to published trial data and may be more generalisable to a UK population.

Conclusion: SGLT2i are very well tolerated and are associated with improvements in multiple metabolic and clinical parameters in UK real-world practice. Relatively small differences were observed between agents for HbA1c and SBP reduction, but not for weight reduction. Further work should focus on establishing the association between individual SGLT2i agents and hard cardiorenal end points in the real world.

References

National Institute of Diabetes and Digestive and Kidney Diseases. Story of Discovery: SGLT2 inhibitors: harnessing the kidneys to help treat diabetes. 2016; Available from: https://www.niddk.nih.gov/news/archive/2016/story-discovery-sglt2-inhibitors-harnessing-kidneys-help-treat-diabetes#:~:text=The%20first%20SGLT2%20inhibitor%20to,Jardiance%C2%AE)%20in%20August%202014.

Shyangdan DS, Uthman OA, Waugh N. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis. BMJ Open 2016;6(2):e009417. https://doi.org/10.1136/bmjopen-2015-009417

Zaccardi F, Webb DR, Htike ZZ, Youssef D, Khunti K, Davies MJ. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis. Diabetes, Obesity Metab 2016;18(8):783-94. https://doi.org/10.1111/dom.12670

Baigent C, et al; The Nuffield Department of Population Health Renal Studies Group and the SGLT2 inhibitor Meta-Analysis Cardio- Renal Trialists’ Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022;400(10365): 1788-801. https://doi.org/10.1016/S0140-6736(22)02074-8

Crabtree TSJ, Ryder RE. The effect of sodium-glucose link transporter 2 inhibitors on heart failure end points in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Br J Diabetes 2021;21(2): 186-91. https://doi.org/10.15277/bjd.2021.307

Tsai W-C, Hsu S-P, Chiu Y-L, et al. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open 2022;12(10): e060655. https://doi.org/10.1136/bmjopen-2021-060655

National Institute for Health and Care Excellence. Type 2 diabetes [2015] (update 2022). 2022.

Crabtree TS, Bickerton A, Elliott J, et al. Effect of empagliflozin on albuminuria, eGFR and serum creatinine: updated results from the ABCD nationwide empagliflozin audit. Br J Diabetes 2021;21:62- 6. https://doi.org/10.15277/bjd.2021.288

Crabtree TS, Yadagari M, Gallen I, et al. The effect of dapagliflozin on alanine aminotransferase as a marker of liver inflammation: updated results from the ABCD dapagliflozin audit. Br J Diabetes 2020;20(1):19-24. https://doi.org/10.15277/bjd.2020.239

Crabtree TS, Winocour P, Darzy K, et al. Effects of canagliflozin are mostly observed at first follow-up, within 6 months of commencement: results for the ABCD canagliflozin audit. Br J Diabetes 2020;20(2):113-16. https://doi.org/10.15277/bjd.2020.258

Crabtree T, Gallagher A, Gallen I, et al. The effect of sodium-glucose link transporter 2 inhibitors (SGLT2i) on microalbuminuria: cross- class analysis from the ABCD audit programme. Diabetic Medicine 2022;39(S1):A41(P230). https://doi.org/10.1111/dme.14810

Marshall A, Altman DG, Holder RL, Royston P. Combining estimates of interest in prognostic modelling studies after multiple imputation: current practice and guidelines. BMC Med Res Methodol 2009;9:57. https://doi.org/10.1186/1471-2288-9-57

Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 2015 373(22):2117-28. https://doi.org/10.1056/NEJMoa1504720

Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis. Ann Intern Med 2013;159(4):262-74. https://doi.org/10.7326/0003-4819-159-4-201308200-00007

Sokolov V, Yakauleva T, Chu L, et al. Differentiating the sodium- glucose cotransporter 1 inhibition capacity of canagliflozin vs. dapagliflozin and empagliflozin using quantitative systems pharmacology modeling. CPT Pharmacometrics Syst Pharmacol 2020;9(4):222-9. https://doi.org/10.1002/psp4.12498

Benham JL, Booth JE, Sigal J, et al. Systematic review and meta- analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes. Int J Cardiol Heart Vasc 2021;33:100725. https://doi.org/10.j.ijcha.2021.100725

Downloads

Published

2024-06-29

Issue

Section

Original Research

Most read articles by the same author(s)